knowledge -WSS

knowledge

author：entertainment 2025-09-04 04:43:27 - browse：6186

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Violet CEO on training clinicians to promote more inclusive care

WSS

Three trends to watch in biotech in 2024

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Why health care costs have stayed mostly flat since 2010

Medicare drug price negotiation hasn't dried up venture capital

Websites selling Wegovy, Zepbound ingredients targeted by FDA

knowledge

knowledge

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Hospitals owned by private equity see complications spike 25%

What does generative AI mean for health care? We asked experts

AMAs digital advisors table RPM coding reform proposal, again

Trump demands the U.S. pay no more for drugs than other countries … again

Juul documents reveal insider tactics on political lobbying

Jerome Adams on the need for new antivirals for Covid

Tome Biosciences co

Sports medicine is finally prioritizing gender equality

Grail spinoff by Illumina should end disastrous merger attempt

entertainment

Latigo launches with $135 million for Vertex

Three trends to watch in biotech in 2024

Can sheer will power keep patients alive in their dying hours?

Keeping primary care docs in field isn't impossible, says AAFP CEO

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

explore

Wikipedia

Wikipedia

hotspot